Skip to content

News & calendar

news: as of 2026-10-12
What the marks mean

Importance is a model-assigned 1–5 on published stories, not a market forecast.

Impact on a scheduled row is a company-prominence tier (High/Medium from graph centrality and size; Low only on curated minor events), not a magnitude forecast.

An earnings date marked confirmed is company-confirmed by Yahoo Finance; estimated is not yet announced. Unmarked rows carry no recorded provenance.

Economic releases are macro and carry no industry, so they stay in every view. A release with no value has not printed yet and says so rather than showing a zero.

Upcoming events across the tracked universe; past events are archived, with outcomes added where available — curated and cited, never fabricated. A past row without one reads “outcome pending”.

A lock-up or index change row adds one line of arithmetic — shares becoming sellable, or shares index funds must buy, as a share of float — read off the prospectus or the index methodology, with both numbers cited in the row. It states the mechanics, not a price move. A lock-up date derived as IPO + 180 days stays estimated until the company states it.

Ahead

scheduled · today and tomorrow · calendar refreshed 2026-10-12

Mon · 12 Oct · today

Tue · 13 Oct

Behind

published · newest first

Tue · 14 Jul

product

08:42
Google News: Akeso

Phase II Trial of Cadonilimab(PD-1/CTLA-4) Combination Regimen Launches in the United States for Perioperative Treatment of Gastric Cancer

Akeso launched a U.S. Phase II trial of its cadonilimab PD-1/CTLA-4 combination regimen for perioperative gastric cancer treatment.

Markets open original ↗

regulation

07:47
Google News: Simulations Plus

Johnson Fistel Investigates Simulations Plus Following Revenue Guidance Cut and Accounting Disclosures

Law firm Johnson Fistel is investigating Simulations Plus following a revenue guidance cut and accounting disclosures.

Markets open original ↗

earnings

07:22
Google News: Medipal Holdings Corporation

Medipal Lifts Net Profit Outlook After Paltac Takeover, Trims Operating Guidance

Medipal raised its net profit outlook following the Paltac acquisition while trimming its operating guidance.

Markets open original ↗

partnership

06:30
AstraZeneca

AstraZeneca licenses oral EGFR inhibitor Zegfrovy from Dizal in up to $1.5B deal

AstraZeneca entered an exclusive global license agreement with Dizal Pharmaceutical for Zegfrovy (sunvozertinib), an oral EGFR inhibitor for EGFR exon 20 insertion NSCLC. AstraZeneca will pay $600 million upfront and up to $900 million in milestones plus tiered royalties for worldwide rights.

Markets open original ↗

regulation

05:09
Google News: Hyundai Rotem

Hyundai Rotem's K2 Acquires NATO Quality Certification

Hyundai Rotem's K2 tank acquired NATO quality certification.

Markets open original ↗

The wire

everything that arrived · 7 days